Compare 8x8 Inc (EGHT) vs Cassava Sciences Inc (FLNA) Price & Performance

EGHT trades at $2.01, down 6.07% today, with a neutral technical signal. The company reported a net loss of $27.21M for 2025 despite revenue of $715.07M, but recent quarters show earnings beats. Analyst consensus is a $3.13 price target with a mixed buy/hold sentiment. Positive developments include AI product expansions and a new partner program aimed at growth.

The outlook hinges on execution toward profitability; projected 2026 net income of $5M offers optimism, but high debt and thin margins pose risks. The stock presents a speculative opportunity if operational improvements continue, though volatility and competitive pressures remain key concerns for investors.

FLNA trades at $0.9459, down 2.65% today, with a bearish technical signal from moving averages. The company, focused on therapies for Tuberous Sclerosis Complex-related epilepsy, reported a net loss of $90.97M for 2025 and negative cash flows, though recent quarters showed earnings beats. Analyst consensus is 66.7% buy, but negative ROE of -55.79% and ROA of -35.34% highlight financial strain.

Outlook remains speculative given deep losses and cash burn; upside hinges on successful drug development, while risks include funding needs and clinical trial outcomes. The low P/B of 0.71 may attract value hunters, but profitability is distant.